磷酸二酯酶-4抑制剂治疗掌跖脓疱病的研究进展  

Research progress on phosphodiesterase 4 inhibitors in the treatment of palmoplantar pustulosis

作　　者：姚心怡 高文丽 李娟 张峻岭[2] YAO Xinyi;Gao Wenli;LI Juan;ZHANG Junling(Graduate School of Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,Tianjin 300120,China)

机构地区：[1]天津中医药大学研究生院,天津301617 [2]天津市中医药研究院附属医院,天津300120

出　　处：《皮肤性病诊疗学杂志》2024年第11期789-794,共6页Journal of Diagnosis and Therapy on Dermato-venereology

摘　　要：掌跖脓疱病(PPP)是一种慢性复发性炎症性皮肤疾病,现有治疗手段不能满足患者需求。磷酸二酯酶-4(PDE-4)是参与免疫细胞体内平衡的关键酶,在PPP相关的多种炎症信号传导途径中充当下游介质,广泛调节免疫反应。口服PDE-4抑制剂阿普米司特(Apremilast)在PPP的临床实验中表现优越,克立硼罗软膏(Crisaborole)也有报道可使皮损持续改善。本文就PDE-4抑制剂治疗PPP的研究进展作一概述。Palmoplantar pustulosis(PPP)is a chronic recurrent inflammatory skin disease.Existing therapeutic methods cannot meet the demand by patients.Phosphodiesterase-4(PDE-4)is a key enzyme involved in the balance of immunocytes.It acts as a downstream mediator in the signaling pathways of a variety of cytokines which are associated with palmoplantar pustulosis and extensively regulate immune responses.Apremilast,as representative of the oral PDE-4 inhibitors,displays superior efficacy in clinical trials against palmoplantar pustulosis.Crisaborole has also been regulate to induce sustained improvement in skin lesions.This article reviews the research progress on PDE-4 inhibitors in treatment of palmoplantar pustulosis.

关 键 词：掌跖脓疱病 磷酸二酯酶-4抑制剂 阿普米司特 克立硼罗 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]